Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response.
Dalgard O, Bjøro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, Reichard O, Myrvang B, Sundelöf B, Ritland S, Hellum K, Frydén A, Florholmen J, Verbaan H; North-C Group. Dalgard O, et al. Hepatology. 2008 Jan;47(1):35-42. doi: 10.1002/hep.21975. Hepatology. 2008. PMID: 17975791 Clinical Trial.
Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon alpha-2b and ribavirin.
Mangia A, Dalgard O, Minerva N, Verbaan H, Bacca D, Ring-Larsen H, Copetti M, Carretta V, Piazzolla V, Cozzolongo R, Mottola L, Andriulli A. Mangia A, et al. Among authors: ring larsen h. Aliment Pharmacol Ther. 2010 Jun;31(12):1346-53. doi: 10.1111/j.1365-2036.2010.04290.x. Epub 2010 Mar 8. Aliment Pharmacol Ther. 2010. PMID: 20222909 Free article.
Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
Janssen HL, Gerken G, Carreño V, Marcellin P, Naoumov NV, Craxi A, Ring-Larsen H, Kitis G, van Hattum J, de Vries RA, Michielsen PP, ten Kate FJ, Hop WC, Heijtink RA, Honkoop P, Schalm SW. Janssen HL, et al. Hepatology. 1999 Jul;30(1):238-43. doi: 10.1002/hep.510300113. Hepatology. 1999. PMID: 10385662 Clinical Trial.
Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study.
Nordøy I, Krarup HB, Bell H, Christensen PB, Elgjo K, von der Lippe B, De Muckadell OS, Maeland A, Ring-Larsen H, Samdal HH, Simmonds P, Skaug K, Tage-Jensen U, Schrumpf E. Nordøy I, et al. Scand J Gastroenterol. 1997 Dec;32(12):1256-60. doi: 10.3109/00365529709028156. Scand J Gastroenterol. 1997. PMID: 9438325 Clinical Trial.
Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.
Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K. Christensen PB, et al. Among authors: ring larsen h. Scand J Gastroenterol. 2012 Sep;47(8-9):1115-9. doi: 10.3109/00365521.2012.694905. Epub 2012 Jun 7. Scand J Gastroenterol. 2012. PMID: 22670704
98 results